The bill
Risky Research Review Act
S. 854, 119th Congress β read as touching Biotech & Research.
Sponsored by
Sen. Paul, Rand [R-KY]
ID: P000603
Follow the money
The bill
S. 854, 119th Congress β read as touching Biotech & Research.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
20 itemised contributions to this sponsor, pulled from FEC filings.
Track this bill's progress through the legislative process
Latest Action
Placed on Senate Legislative Calendar under General Orders. Calendar No. 164.
September 16, 2025
π Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
Another masterpiece of legislative theater, courtesy of the esteemed members of Congress. The Risky Research Review Act (S 854) - a bill that promises to protect us from the dangers of dual-use research while actually serving as a Trojan horse for bureaucratic expansion and special interest pandering.
**Main Purpose & Objectives:** The bill's stated purpose is to establish the Life Sciences Research Security Board, which will supposedly review and regulate "dual use research of concern" - research that could potentially be used for nefarious purposes. But let's not be naive; this board will likely become a rubber stamp for the interests of powerful lobbies and government agencies.
**Key Provisions & Changes to Existing Law:** The bill creates a new chapter in Title 31, United States Code, establishing the Life Sciences Research Security Board. The board will have sweeping powers to review research proposals, impose regulations, and even conduct audits. But don't worry, it's all for our safety - or so they claim.
**Affected Parties & Stakeholders:** The usual suspects will benefit from this bill: government agencies seeking more power, researchers looking for funding and prestige, and lobbyists representing the interests of pharmaceutical companies and biotech firms. Meanwhile, taxpayers will foot the bill for this bureaucratic expansion, and actual research may be stifled by the added regulatory burden.
**Potential Impact & Implications:** This bill is a classic case of "mission creep." It starts with a seemingly noble goal - protecting us from dual-use research - but ultimately becomes a vehicle for government overreach and special interest influence. The board will likely become a tool for suppressing research that challenges the status quo or threatens powerful interests.
In medical terms, this bill is akin to a patient presenting with symptoms of bureaucratic bloat and regulatory fever. The diagnosis? A bad case of "Legislative-itis" - a disease characterized by an excessive growth of government agencies, fueled by special interest money and a disregard for individual liberties.
Treatment? A healthy dose of skepticism, followed by a strong prescription of transparency and accountability. But don't hold your breath; this patient is likely to remain in a state of chronic bureaucratic illness, with the Risky Research Review Act serving as just another symptom of a deeper disease - the corruption and cowardice that plagues our legislative system.
Sen. Paul, Rand [R-KY]
Congress 119 β’ 2024 Election Cycle
No PAC contributions found
No organization contributions found
No committee contributions found
This bill has 1 cosponsors. Below are their top campaign contributors.
ID: P000595
Top Contributors
10
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 51 nodes and 23 connections (47 secondary connections hidden)
Total contributions: $97,400
Showing top 19 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 5 harmed.
The bill establishes a Life Sciences Research Security Board that reviews and can block Federal funding for high-risk life sciences research, including gain of function research and dual use research of concern involving high-consequence pathogens. This imposes regulatory oversight and potential delays or denials of funding for biotech firms engaged in such research, constituting a clear cost (new regulation, enforcement, market contraction). Sections 7904, 7905, and 7906 detail the Board's auth
The bill's review process applies to life sciences research, which includes pharmaceutical and biomedical research (as defined in section 7901(10)(B)). Pharmaceutical companies receiving Federal funding for research involving high-consequence pathogens or gain of function research would be subject to Board approval, potentially delaying or blocking awards. This constitutes a clear cost via new regulatory oversight and enforcement mechanisms under sections 7905 and 7906.
The bill creates a Life Sciences Research Security Board that reviews and can block Federal funding for high-risk life sciences research, which includes pharmaceutical and biomedical research. This could reduce funding for health insurance-related research (e.g., drug development, vaccine research) that insurers may rely on for coverage decisions, potentially harming the health insurance industry by limiting innovation in treatments they cover. Section 7906(a)(1)(B) gives the Board authority to
Hospitals and health systems that conduct life sciences research (e.g., clinical trials, biomedical studies) with Federal funding may be subject to the Board's review if their research involves high-risk life sciences as defined. This could delay or restrict funding for such research, imposing a cost via new regulatory requirements. Section 7901(10) includes biomedical research, and sections 7905-7906 apply to agencies awarding such funding, which includes NIH-funded hospital research.
Medical device companies engaged in life sciences research (e.g., biomaterials, implantable devices, diagnostics) that receive Federal funding for research involving high-consequence pathogens or gain of function research would fall under the Board's purview. This could impose delays or denials of funding, representing a clear cost via new regulatory oversight. Section 7901(10) includes biomedical research and techniques, which encompasses medical device R&D.
For each industry this bill affects, here's what the sponsor (Sen. Paul, Rand [R-KY])received from donors associated with that industry during the 2022βpresent cycles. Donations are not proof of intent β they are a record of who funds the people writing the law.
A bill to amend title 3, United States Code, to prescribe a process to authorize certain activities at the Executive Residence at the White House, and for other purposes.
119/s/4486
A bill to remove restrictions from a parcel of land in Paducah, Kentucky.
119/s/601
Federal Reserve Transparency Act of 2025
119/s/2327